Açaí Berry (Euterpe oleracea Mart.): A Comprehensive Reference
1. Identity, Botanical Classification, and Common Forms
1.1 Botanical and Chemical Identity
The açaí palm (Euterpe oleracea Mart.), a species belonging to the Arecaceae family, has been cultivated for thousands of years in tropical Central and South America as a multipurpose dietary plant. There are two main species of the Euterpe genus that produce açaí, and while there are several differences between them, these differences remain largely unknown to producers and consumers alike. The primary commercial species is Euterpe oleracea, while Euterpe precatoria (known as "açaí-do-mato" or solitary açaí) is harvested regionally. The fruit is technically a drupe — a small, round berry with a deep purple hue, approximately the size of a grape, with a thin outer skin covering a pulpy mesocarp and a large, inedible seed. It grows abundantly in the Amazon estuary and on floodplains, in swamps, and in upland regions, and also serves as a major food source for native and lower-class people of Brazil, Colombia, and Suriname.
Fresh açaí berries are essentially unattainable outside of Brazil, and the current literature lacks reports of successful cultivation of açaí trees beyond the Amazon region. Fresh açaí berries have a short shelf life, spoiling within 24 hours of being harvested.
1.2 Common Preparations and Dosage Forms
Because of the fruit's extreme perishability, commercial açaí is almost exclusively processed before export. Available preparations include:
- Frozen pulp/purée: The most traditional processed form, used in açaí bowls and smoothies. In clinical studies, the Sambazon® frozen smoothie pack — a pasteurized puree containing approximately 11% dry açaí solids — has been used as a standardized preparation.
- Freeze-dried powder: Used extensively in research due to its concentrated and stable phytochemical profile. A standardized freeze-dried açaí fruit pulp/skin powder has been used as the basis for most detailed analytical and phytochemical studies.
- Juice, oil, extract capsules, and topical preparations are also commercially available.
- Beverages: Clarified juice and whole-pulp juice have both been studied in human pharmacokinetic trials, with pulp preparations delivering higher anthocyanin absorption than clarified juice.
2. Traditional and Historical Use
2.1 Indigenous Amazonian Traditions
Açaí berries grow on the tall, slender palms of the Euterpe oleracea tree, native to the floodplains of the Amazon basin in South America. For centuries, indigenous tribes such as the Tupí-Guaraní people have revered the açaí palm for its nutritional and medicinal properties, using the berries as a staple food source and natural remedy.
For centuries, the açaí tree was only consumed by indigenous communities along the Amazon River basin. Tribes like the Shuar, the Awá, and the Yanomami used açaí trees for medicinal and culinary purposes, creating a rich tradition of their use. Indigenous tribes also traditionally harvested açaí palm hearts, leaves, and bark, utilizing the entire palm tree for food and medicinal purposes, making it one of the most important plants in Amazonian culture.
Following the harvest, açaí berries were traditionally processed by soaking them in water to soften the pulp. They would sometimes be mashed into a paste and eaten alone, or mixed with other mashed fruits to form a soft, fruity meal. Drinking açaí was also a common practice, combining açaí pulp with water or another liquid to create a nutritious beverage. Açaí porridge — a combination of açaí pulp and tapioca or cassava flour — was another traditional dish.
Historically, açaí has been in Brazilian diets for centuries, often eaten as a juice or pudding-like pulp. The tribes in the Amazon rainforest region used açaí to treat ailments as medicine and for health in "strengthening the immune system, fighting off infection, heart health, and even a sexual stimulant."
Traditional plant use reports also indicate the beneficial effects of açaí juice on fever, pain, and flu.
2.2 Expansion Beyond the Amazon and Modernization
In cities like Rio de Janeiro and São Paulo, street vendors and juice bars began blending açaí pulp with sugar and guaraná syrup, serving the resulting mixture in bowls topped with granola, bananas, and sometimes honey. This urban adaptation transformed açaí from a simple sustenance food into a sweet, refreshing treat that appealed to Brazil's coastal culture. By the 1990s, açaí had become a quintessential part of Brazil's beach culture, and its journey to the rest of the world began in the early 2000s, thanks to advancements in food preservation and distribution.
3. Key Constituents and Active Compounds
3.1 Polyphenols: Anthocyanins
Among many findings in the freeze-dried açaí fruit pulp/skin, anthocyanins (ACNs), proanthocyanidins (PACs), and other flavonoids were found to be the major phytochemicals. Two ACNs, cyanidin-3-glucoside and cyanidin-3-rutinoside, were found to be the predominant ACNs, with the total content of ACNs measured at 3.1919 mg/g dry weight (DW). Açaí has four main anthocyanin analytes: cyanidin 3-glucoside, cyanidin 3-sambubioside, cyanidin 3-rutinoside, and peonidin 3-rutinoside.
Chemical composition analysis revealed higher levels of total polyphenol content in purple açaí samples (4.3–44.7 gallic acid equivalents mg/g commercially, 30.2–42.0 mg/g non-commercially). The major anthocyanin compounds found in purple açaí samples were cyanidin-3-glucoside and cyanidin-3-rutinoside with total concentrations in the range of 3.6–14.3 cyanidin-3-glucoside equivalents mg/g.
3.2 Proanthocyanidins (Condensed Tannins)
Polymers were found to be the major PACs in freeze-dried açaí, with the concentration of total PACs calculated at 12.89 mg/g DW. The oligomeric proanthocyanidins were quantified in the range of 1.5–6.1 procyanidin B1 equivalents mg/g. The profile of proanthocyanidins in freeze-dried açaí is very similar to that of the blueberry. Proanthocyanidins have been found in most berries and have been found to possess strong antioxidant capacity, so they may contribute, at least partly, to overall in vitro antioxidant capacity.
3.3 Other Flavonoids
Other flavonoids, namely homoorientin, orientin, isovitexin, scoparin, and taxifolin deoxyhexose, along with several unknown flavonoids, were also detected. The açaí extracts also contain polyphenolic components with antioxidant properties including orientin, isoorientin and vanillic acid. Resveratrol was found in açaí but at a very low concentration.
3.4 Fatty Acids
Total polyunsaturated fatty acid, total monounsaturated fatty acid, and total saturated fatty acids contributed to 11.1%, 60.2%, and 28.7% of total fatty acid in freeze-dried açaí, respectively. Oleic acid (53.9%) and palmitic acid (26.7%) were the two dominant fatty acids. The exceptional fiber content of açaí (44.2 g per 100 g dry weight) is notable, as is its unusual lipid composition — açaí is one of the only berries with substantial fat content, predominantly the monounsaturated oleic acid.
3.5 Sterols, Amino Acids, and Minerals
Nineteen amino acids were found in freeze-dried açaí, with total amino acid content determined to be 7.59% of total weight. Total sterols accounted for 0.048% by weight, and the three sterols β-sitosterol, campesterol, and stigmasterol were identified. Moreover, açaí presented significant levels of calcium, magnesium, manganese, iron, zinc, and copper — essential minor and trace elements — in comparison with other berries.
4. Mechanisms of Action
4.1 Antioxidant Activity
Açaí extracts have a range of polyphenolic components with antioxidant properties; the presence of these substances is linked mainly to the antioxidant, anti-inflammatory, antiproliferative, and cardioprotective activities. Açaí's ORAC (Oxygen Radical Absorbance Capacity) value on a dry-weight basis is approximately 10–40 times higher than other common berries. However, in vitro ORAC values do not directly predict in vivo health benefits.
4.2 Anti-inflammatory Pathways
Açaí extract was noted to decrease COX-2, TNF-α, and NF-κβ expression induced by lipopolysaccharide (LPS) in human colon myofibroblasts. It also protected human vascular endothelial cells against oxidative stress and inflammation, downregulated IL-6 and IL-8 expression at mRNA and protein levels, and inhibited gene expression of adhesion molecules and NF-κB activation. These in vitro findings collectively suggest that açaí's anti-inflammatory action may proceed through inhibition of the NF-κB signaling pathway as well as via suppression of COX and inducible nitric oxide synthase (iNOS) pathways.
4.3 Neuroprotective Mechanisms
L-glutamate caused a significant reduction in cell viability, ATP, and mitochondrial membrane potential (MMP) levels and increased reactive oxygen species (ROS) production in neuroblastoma cells. Co-application of both açaí berry extracts with L-glutamate provided neuroprotection, with sustained cell viability, decreased LDH production, restored ATP and MMP levels, and reduced ROS levels. Fractionation and analysis identified several phytochemical antioxidants that may have provided neuroprotective effects.
4.4 Bioavailability and Pharmacokinetics in Humans
A crossover pharmacokinetic study in 12 healthy volunteers compared açaí pulp and clarified juice consumed at 7 mL/kg body weight after overnight fasting. Peak plasma anthocyanin concentration (Cmax) was 2,321 ng/L for pulp vs. 1,138 ng/L for juice, with time to peak at 2.2 hours for pulp and 2.0 hours for juice. Area under the curve (AUClast) was 8,568 ng·h/L for pulp vs. 3,314 ng·h/L for juice, and plasma antioxidant capacity increased up to 3-fold for pulp and 2.3-fold for juice.
A recent study quantified the polyphenols and their metabolite content in the cerebrospinal fluid of 90 individuals at risk of developing dementia using chromatography–mass spectrometry, revealing that polyphenols can cross the blood–brain barrier through passive diffusion or by utilizing transporters, thereby promoting neuroprotective effects.
5. Scientific Evidence by Health Area
5.1 Antioxidant Status and Oxidative Stress
In vitro and in vivo studies have shown that açaí possesses antioxidant and anti-inflammatory properties. Clinical trials have suggested that açaí can protect against metabolic stress induced by oxidation, inflammation, vascular abnormalities, and physical exertion.
An integrative review of human clinical trials has suggested that açaí may contribute to improved antioxidant capacity, metabolic stress, and inflammation. Three RCTs of açaí were evaluated in a 2023 systematic review of berry RCTs, with intervention durations ranging from 7 days to 24 weeks.
Evidence strength: A 2023 systematic review evaluating oxidative stress biomarkers across 28 RCTs of berry consumption (including açaí) found that only 32% of the approximately 56 biomarkers evaluated showed statistically significant beneficial results, while 68% showed no significant differences. Açaí consistently increases plasma antioxidant capacity and reduces some markers of oxidative stress (particularly 8-isoprostane and IFN-γ) in human trials, with effects most pronounced in individuals with metabolic stress. However, core inflammatory markers like CRP, TNF-α, and IL-6 are generally not affected, and the clinical significance of transiently elevated plasma ORAC is uncertain.
5.2 Cardiovascular and Metabolic Health
Pilot study (n=10), open-label: This was an open-label pilot study conducted with 10 overweight adults (BMI ≥ 25 kg/m² and ≤ 30 kg/m²) who took 100 g açaí pulp twice daily for 1 month. There were beneficial effects, compared to controls, on antioxidant enzyme activity, measured as an increase in serum paraoxonase, which is associated with prevention/inhibition of lipoprotein oxidation. In this uncontrolled pilot study, consumption of açaí fruit pulp reduced levels of selected markers of metabolic disease risk in overweight adults, indicating that further studies are warranted. The study lacked a placebo control arm, limiting the interpretability of its findings.
RCT — metabolic syndrome (n=37): In a randomized, double-blind, placebo-controlled trial, 37 individuals with metabolic syndrome consumed 325 mL of an açaí beverage (containing 1,139 mg/L gallic acid equivalents of total polyphenolics) twice daily for 12 weeks. Significant reductions were found in interferon-gamma (IFN-γ, −76.2%) and urinary 8-isoprostane (−31.2%). However, the prespecified primary outcome — high-sensitivity C-reactive protein (hs-CRP) — was not significantly altered, nor were TNF-α or IL-6.
Vascular function (acute, crossover study, overweight men): Consumption of a flavonoid-rich açaí meal was associated with acute improvements in vascular function and a reduction in total oxidative status in healthy overweight men (American Journal of Clinical Nutrition, 2016).
Evidence strength: The available RCT evidence is limited in number and scale. Some improvements in select oxidative stress and inflammatory markers have been demonstrated in controlled trials, particularly IFN-γ and 8-isoprostane. Although several studies have been conducted in vitro and with animals, little is known about the potential health benefits in humans aside from an increase in plasma antioxidant capacity.
5.3 Oncology — Prostate Cancer
Phase II clinical trial (n=21): A phase II, Simon 2-stage clinical trial was conducted in patients with biochemically recurrent prostate cancer with a primary endpoint of prostate-specific antigen (PSA) response. Patients were asymptomatic with a rising PSA of at least 0.2 ng/mL and were treated with twice daily intake of Açaí Juice Product until PSA progression. Twenty-one patients were enrolled in the first stage of the trial. Only 1 of 21 patients (4.8%) achieved a PSA response. PSA doubling time was lengthened in 71% of patients (95% CI: 48–89%), but the trial did not meet its primary endpoint for PSA response.
A 2018 systematic review of açaí's anticancer potential concluded that while in vitro and animal data are promising, no human studies have definitively demonstrated anticancer effects. The review cautioned that açaí is frequently promoted to cancer patients with unsubstantiated claims. Açaí demonstrates consistent anticancer activity in laboratory and animal models, but the only human cancer trial failed to meet its primary endpoint.
Evidence strength: Preclinical (in vitro and animal) evidence for antiproliferative and pro-apoptotic effects is substantial. Human evidence is limited to a single Phase II trial that did not meet its primary endpoint, making conclusions about anticancer efficacy premature.
5.4 Neuroprotection and Cognitive Function
Euterpe oleracea has been given much attention among scientists due to its high antioxidant capacity compared to other fruits and berries. Açaí pulp composition analysis found that it contains various biologically active phytochemicals. Research has focused on current evidence relating to açaí berry neuroprotection mechanisms and its efficacy in preventing or reversing neurodegeneration and age-related cognitive decline.
In recent years, there has been a growing interest in investigating the neuroprotective effects of açaí, with the potential for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease, mainly due to the increasing aging of the population.
Although there are no clinical studies using extracts prepared from the pulp and seeds of the açaí berry on cognition, data from the literature have investigated the effects of anthocyanin administration in patients at increased risk of developing dementia, in which they used 320 mg of anthocyanins per day, which could be a starting point for transposing the concentrations used in experimental studies.
Animal studies have demonstrated that supplementation with açaí pulp or extracts improved memory performance and reduced markers of oxidative damage in the brain.
Evidence strength: While no studies have tested açaí berry interventions for neuroprotection in humans, açaí berries have strong antioxidant effects, though benefits for humans are not as consistent as those in preclinical studies. All neuroprotective evidence currently derives from cell culture and animal models; no human clinical trials exist.
5.5 Inflammatory Pathways (General)
Açaí improves anti-inflammatory status by directly reducing the synthesis of proinflammatory cytokines and expression of proinflammatory signaling pathways, including COX-2, FMLP, IL-1β, IL-6, IL-8, IL-12, NF-κB, iNOS, PGs, MAPK, TGF-β, and TNF-α. These findings are predominantly derived from in vitro models and preclinical animal studies; the translation to consistent clinical benefit in humans remains uncertain, as confirmed by RCT data showing that primary inflammatory biomarkers such as CRP, TNF-α, and IL-6 are generally not significantly altered in human trials.
5.6 Exercise Performance and Muscle Stress
A small number of human studies have investigated açaí's effect on exercise-induced oxidative stress. A crossover study in 12 physically active young men (average age 28) involved 40 g of dehydrated açaí seed powder consumed daily for 7 days. A separate study reported that an açaí functional beverage reduced muscle stress in elite athletes (Gonçalves et al., Applied Physiology, Nutrition, and Metabolism, 2015). These findings are preliminary given the very small sample sizes and single-study status.
6. Body Systems and Health Areas of Association
In vitro and in vivo studies showed that açaí possesses antioxidant and anti-inflammatory properties and exerts cardioprotective, gastroprotective, hepatoprotective, neuroprotective, renoprotective, antilipidemic, antidiabetic, and antineoplastic activities. The evidence underlying these associations varies considerably by body system:
- Cardiovascular system: RCT evidence exists for short-term effects on select oxidative stress markers; effects on lipid profiles and primary inflammatory markers are inconsistent.
- Metabolic/endocrine system: Pilot and RCT data show some metabolic benefits in overweight and metabolic syndrome populations; glucose and lipid outcomes are generally not significantly improved.
- Central nervous system: Evidence is limited to in vitro and animal models; no human trials exist.
- Oncology: Strong preclinical data; the only human trial (prostate cancer, Phase II) did not meet its primary endpoint.
- Gastrointestinal system: Predominantly preclinical data only.
- Renal system: Preclinical (animal model) data only — no human clinical evidence.
- Liver: Predominantly hepatoprotective evidence from animal models; one clinical case report of potential hepatotoxicity from supplement use.
7. Dosage Forms and Dosages Reported in Studies
The following dosages derive exclusively from clinical or pharmacokinetic studies as described in peer-reviewed sources:
- Frozen açaí pulp: 100 g twice daily (200 g/day total) for 30 days, in an open-label pilot study of 10 overweight adults.
- Açaí beverage (standardized polyphenolic content): 325 mL twice daily (650 mL/day) for 12 weeks, in a randomized, double-blind, placebo-controlled trial of 37 individuals with metabolic syndrome. The beverage contained 1,139 mg/L gallic acid equivalents of total polyphenolics.
- Açaí pulp or clarified juice (pharmacokinetic study): 7 mL/kg body weight as a single dose, in a crossover study of 12 healthy volunteers.
- Açaí Juice Product (cancer trial): Twice daily intake until PSA progression, in a Phase II trial of 21 patients with biochemically recurrent prostate cancer.
No universally established or pharmacopoeia-recognized dose for açaí as a dietary supplement currently exists. Dosages across commercial products vary widely and cannot be standardized without validated polyphenolic content specifications.
8. Safety Considerations and Drug Interactions
8.1 General Safety Profile
In a clinical trial with healthy volunteers, consumption of açaí pulp and juice did not result in any reported adverse effects. The study showed increased plasma antioxidant capacity after consumption without identifying safety concerns during the acute trial period. However, comprehensive long-term safety data in humans are still lacking, and only a few human studies have been conducted to date.
8.2 Hepatotoxicity
Based on literature searches, a single peer-reviewed clinical case has reported cholestatic jaundice (drug-induced liver injury/potential toxicity) linked to daily consumption of an açaí berry supplement. While açaí has been predominantly reported to exert hepatoprotective effects in in vivo studies due to its antioxidant and anti-inflammatory properties, the possibility of adverse outcomes cannot be completely ruled out. An analysis of the FDA CAERS (2007–2024) revealed sporadic reports of adverse events involving gastrointestinal (50.5%), cardiovascular (17.5%), and hepatic (7.8%) systems following consumption of açaí-containing products.
8.3 Drug Interactions
Despite its popularity, limited data exist on açaí's ability to modulate drug-metabolizing enzymes and transporters — critical determinants of pharmacokinetic botanical–drug interactions. A study evaluated the cytotoxicity and induction potential of açaí extracts on cytochrome P450 (CYP450) enzymes and drug transporters using physiologically relevant in vitro models.
There was a significant change in the AUC₀–t and Cmax of atorvastatin, alogliptin, and empagliflozin after co-administration with açaí berry in a rat model. Further studies are recommended to confirm the clinical significance of these interactions.
Açaí's drug interactions have not been well-studied in humans. The available evidence comes primarily from animal models and theoretical considerations. No severe drug interactions with açaí have been confirmed in human studies.
Because of its antioxidant effects, açaí may theoretically interfere with the actions of certain chemotherapy drugs.
8.4 Adulteration of Commercial Products
Some açaí supplements on the market may not actually contain açaí. Concerns have been raised about some products labeled as "açaí berry" that have been found to contain sibutramine, a substance banned in several countries due to cardiovascular risks.
8.5 Chagas Disease Risk from Unprocessed Juice
In 2006, a total of 178 cases of acute Chagas disease were reported from the Amazonian state of Pará, Brazil. Eleven occurred in Barcarena and were confirmed by visualization of parasites on blood smears, with oral transmission implicated by consumption of açaí palm fruit. During 1968–2005, a total of 311 of 437 acute Chagas disease cases reported in this region were related to 62 outbreaks in which the suspected mode of transmission was consumption of açaí. Açaí is crushed to produce a paste or beverage, and most of the Amazonian population consumes açaí juice daily. Contamination is believed to be caused by triatomine stools on the fruit or insects inadvertently crushed during processing.
A significant safety concern specific to raw, unpasteurized açaí juice in South America is contamination with Trypanosoma cruzi, the parasite that causes Chagas disease. Multiple outbreaks of orally transmitted Chagas disease have been linked to raw açaí juice in the Brazilian Amazon. Commercially pasteurized açaí products distributed internationally are not associated with this risk.
9. Evidence Quality and Research Gaps
The totality of the evidence on açaí berry must be considered in the context of the research base. Research on the safety and health effects of açaí berries, particularly their antioxidant properties, is still developing. The preponderance of studies are in vitro or animal-based, with a comparatively small number of human clinical trials, most of which are small (n ≤ 37), uncontrolled or weakly controlled, and short in duration. The single human cancer trial did not meet its primary endpoint. Key knowledge gaps include: standardized dosing; long-term safety data; head-to-head comparisons with other polyphenol sources; clinical outcomes for neurological and hepatic endpoints; and validated bioavailability data across different commercial preparations.
References
- Schauss AG et al. Phytochemical and Nutrient Composition of the Freeze-Dried Amazonian Palm Berry, Euterpe oleraceae Mart. (Acai). J Agric Food Chem. 2006;54(22):8598–8603.
- Amazon acai: chemistry and biological activities: a review. PubMed, 2015.
- Matta FV et al. Chemical Composition and Bioactive Properties of Commercial and Non-Commercial Purple and White Açaí Berries. Foods. 2020;9(10):1481. PMC7602988.
- Açaí (Euterpe oleracea Mart.) in Health and Disease: A Critical Review. PubMed, 2023.
- Açaí (Euterpe oleracea Mart.) in Health and Disease: A Critical Review. PMC9965320, 2023.
- Udani JK et al. Effects of Açai (Euterpe oleracea Mart.) berry preparation on metabolic parameters in a healthy overweight population: A pilot study. Nutr J. 2011;10:45. PMC3118329.
- The Effect of Berry Consumption on Oxidative Stress Biomarkers: A Systematic Review of Randomized Controlled Trials in Humans. Antioxidants. 2023;12(7):1443.
- Effect of Dietary Berry Supplementation on Antioxidant Biomarkers in Adults with Cardiometabolic Risks: A Systematic Review of Clinical Trials. PMC10295504.
- Kessler ER et al. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018;17(4):1103–1108. PMC6247557.
- Acai Berry (Euterpe sp.) Extracts Are Neuroprotective against L-Glutamate-Induced Toxicity by Limiting Mitochondrial Dysfunction and Cellular Redox Stress. PMC10144606.
- A Preliminary Assessment of the Nutraceutical Potential of Acai Berry (Euterpe sp.) as a Potential Natural Treatment for Alzheimer's Disease. PMC9370152.
- Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects of Euterpe oleracea Mart. (Açaí) in Improving Cognition Deficits: Potential Therapeutic Implications for Alzheimer's Disease. PMC12252345.
- The Use of Euterpe oleracea Mart. As a New Perspective for Disease Treatment and Prevention. PMC7356995.
- Oral Transmission of Chagas Disease by Consumption of Açaí Palm Fruit, Brazil. PMC2671433.
- Evaluation of in vitro cytotoxicity and induction potential of açaí (Euterpe oleracea) extracts in human hepatocytes. PMC13008539.
- Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study. PubMed, 2022.
- Stratton M. Acai Berry Induced Cholestatic Jaundice. Journal of Medical Cases. 2014.
- Acai Berry — Memorial Sloan Kettering Cancer Center Integrative Medicine Database.
- Alzheimer's Drug Discovery Foundation — Cognitive Vitality Report: Açaí Berries. Updated March 16, 2021.
- Stanfield B. Acai Berry: Benefits, Forms, Dosing, and Side Effects. 2026.
- Neuroprotective activities of acai berries (Euterpe sp.): A review. Journal of Herbmed Pharmacology. 2022;11(2):166–181.
Volver